You are here
Altasciences to present Continuing Education Course at the New York State Bar Association
LAVAL, Quebec, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Altasciences is pleased to announce that Dr. Graham K. Wood, Chief R&D Officer at Altasciences, is presenting at a Continuing Legal Education program entitled Practical Implications of Decriminalized Marijuana for the Legal Practitioner on Wednesday, October 3. The program, which offers 7.0 MCLE credits, is open to members of the New York State Bar Association, who will hear Dr. Wood share his knowledge in the cannabis field, specifically as it relates to Clinical Research.
Dr. Wood has a Ph.D. in Neurology and Neurosurgery from McGill University, has worked as a Research Fellow at the National Institute of Mental Health, and has almost 20 years of experience in designing and conducting clinical pharmacology studies. His deep and broad understanding of the cognitive effects of cannabis is the basis for his testimony to the Canadian Senate on the effects of Cannabis on driving, and he has designed a number of recent first-in-human studies on the safety, tolerability, and cognitive effects of cannabis.
“As the legal landscape around marijuana continues to evolve, reliable clinical research on the effects of cannabis in humans becomes increasingly important, whether the use will be for medical or recreational purposes. It was an educational experience to be part of recent studies in the area, and I look forward to sharing the insights with the New York State Bar,” said Dr. Wood.
The CLE program is organized by the Committee on Continuing Legal Education of the New York State Bar Association, and is sponsored by Barclay Damon LLP. It is also co-sponsored by the Committee on Cannabis Law, the Committee on Continuing Legal Education and the General Practice Section of the New York State Bar Association.
Altasciences is a mid-size CRO focused on early phase drug development, involved in the study of cannabis for over 10 years, with 34 studies completed to date; 14 focused on pharmacokinetics, 1 first-in-human, and one focused on human abuse liability, as well as 18 others.
Altasciences is a mid-size contract research organization that encompasses Algorithme Pharma in Montreal, QC, Vince & Associates Clinical Research in Overland Park, KS, and Algorithme Pharma USA in Fargo, ND, with an overall company focus on supporting early-stage drug development. With over 25 years of industry experience, Altasciences provides clinical services to an international customer base of biopharmaceutical companies. Altasciences’ full-service solutions offering in this critical stage of drug development includes clinical pharmacology, medical writing, biostatistics, data management and bioanalysis.
FOR MORE INFORMATION